Deubiquitinases in Regulated Cell Death: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Conner Chen and Version 1 by Jaewhan Song.

The mechanisms and physiological implications of regulated cell death (RCD) have been extensively studied. Among the regulatory mechanisms of RCD, ubiquitination and deubiquitination enable post-translational regulation of signaling by modulating substrate degradation and signal transduction. Deubiquitinases (DUBs) are involved in diverse molecular pathways of RCD. Some DUBs modulate multiple modalities of RCD by regulating various substrates and are powerful regulators of cell fate.

  • deubiquitinase
  • apoptosis
  • Regulated Cell Death
Please wait, diff process is still running!

References

  1. Clague, M.J.; Coulson, J.M.; Urbé, S. Cellular functions of the DUBs. J. Cell Sci. 2012, 125, 277–286.
  2. Hanpude, P.; Bhattacharya, S.; Dey, A.K.; Maiti, T.K. Deubiquitinating enzymes in cellular signaling and disease regulation. IUBMB Life 2015, 67, 544–555.
  3. Mevissen, T.E.; Komander, D. Mechanisms of deubiquitinase specificity and regulation. Annu. Rev. Biochem. 2017, 86, 159–192.
  4. Das, T.; Shin, S.C.; Song, E.J.; Kim, E.E. Regulation of Deubiquitinating Enzymes by Post-Translational Modifications. Int. J. Mol. Sci. 2020, 21, 4028.
  5. McClellan, A.J.; Laugesen, S.H.; Ellgaard, L. Cellular functions and molecular mechanisms of non-lysine ubiquitination. Open Biol. 2019, 9, 190147.
  6. Wertz, I.E.; Wang, X. From discovery to bedside: Targeting the ubiquitin system. Cell Chem. Biol. 2019, 26, 156–177.
  7. Kwasna, D.; Rehman, S.A.A.; Natarajan, J.; Matthews, S.; Madden, R.; De Cesare, V.; Weidlich, S.; Virdee, S.; Ahel, I.; Gibbs-Seymour, I. Discovery and characterization of ZUFSP/ZUP1, a distinct deubiquitinase class important for genome stability. Mol. Cell 2018, 70, 150–164.e6.
  8. Nijman, S.M.; Luna-Vargas, M.P.; Velds, A.; Brummelkamp, T.R.; Dirac, A.M.; Sixma, T.K.; Bernards, R. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005, 123, 773–786.
  9. Galluzzi, L.; Vitale, I.; Aaronson, S.A.; Abrams, J.M.; Adam, D.; Agostinis, P.; Alnemri, E.S.; Altucci, L.; Amelio, I.; Andrews, D.W. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018, 25, 486–541.
  10. Gómez-Díaz, C.; Ikeda, F. Roles of ubiquitin in autophagy and cell death. In Seminars in Cell & Developmental Biology; Academic Press: Cambridge, MA, USA, 2019; pp. 125–135.
  11. Bhattacharya, S.; Ghosh, M.K. Cell death and deubiquitinases: Perspectives in cancer. BioMed Res. Int. 2014, 2014, 435197.
  12. Wang, F.; Wang, L.; Wu, J.; Sokirniy, I.; Nguyen, P.; Bregnard, T.; Weinstock, J.; Mattern, M.; Bezsonova, I.; Hancock, W.W. Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3+ T-regulatory cells by promoting ubiquitination of Tip60. PLoS ONE 2017, 12, e0189744.
  13. He, Y.; Wang, S.; Tong, J.; Jiang, S.; Yang, Y.; Zhang, Z.; Xu, Y.; Zeng, Y.; Cao, B.; Moran, M.F. The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival. J. Biol. Chem. 2020, 295, 2084–2096.
  14. Li, M.; Chen, D.; Shiloh, A.; Luo, J.; Nikolaev, A.Y.; Qin, J.; Gu, W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002, 416, 648–653.
  15. Liang, L.; Peng, Y.; Zhang, J.; Zhang, Y.; Roy, M.; Han, X.; Xiao, X.; Sun, S.; Liu, H.; Nie, L. Deubiquitylase USP7 regulates human terminal erythroid differentiation by stabilizing GATA1. Haematologica 2019, 104, 2178–2187.
  16. Wang, Y.; Yang, L.; Zhang, X.; Cui, W.; Liu, Y.; Sun, Q.R.; He, Q.; Zhao, S.; Zhang, G.A.; Wang, Y. Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53. EMBO Rep. 2019, 20, e47563.
  17. He, Y.; Li, W.; Lv, D.; Zhang, X.; Zhang, X.; Ortiz, Y.T.; Budamagunta, V.; Campisi, J.; Zheng, G.; Zhou, D. Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity. Aging Cell 2020, 19, e13117.
  18. Brooks, C.; Li, M.; Hu, M.; Shi, Y.; Gu, W. The p53–Mdm2–HAUSP complex is involved in p53 stabilization by HAUSP. Oncogene 2007, 26, 7262–7266.
  19. Lee, G.; Oh, T.-I.; Um, K.B.; Yoon, H.; Son, J.; Kim, B.M.; Kim, H.-I.; Kim, H.; Kim, Y.J.; Lee, C.-S. Small-molecule inhibitors of USP7 induce apoptosis through oxidative and endoplasmic reticulum stress in cancer cells. Biochem. Biophys. Res. Commun. 2016, 470, 181–186.
  20. Tavana, O.; Sun, H.; Gu, W. Targeting HAUSP in both p53 wildtype and p53-mutant tumors. Cell Cycle 2018, 17, 823–828.
  21. Zaman, M.M.-U.; Nomura, T.; Takagi, T.; Okamura, T.; Jin, W.; Shinagawa, T.; Tanaka, Y.; Ishii, S. Ubiquitination-deubiquitination by the TRIM27-USP7 complex regulates tumor necrosis factor alpha-induced apoptosis. Mol. Cell. Biol. 2013, 33, 4971–4984.
  22. Vugmeyster, Y.; Borodovsky, A.; Maurice, M.M.; Maehr, R.; Furman, M.H.; Ploegh, H.L. The ubiquitin–proteasome pathway in thymocyte apoptosis: Caspase-dependent processing of the deubiquitinating enzyme USP7 (HAUSP). Mol. Immunol. 2002, 39, 431–441.
  23. Zhang, W.; Zhang, J.; Xu, C.; Zhang, S.; Bian, S.; Jiang, F.; Ni, W.; Qu, L.; Lu, C.; Ni, R. Ubiquitin-specific protease 7 is a drug-able target that promotes hepatocellular carcinoma and chemoresistance. Cancer Cell Int. 2020, 20, 1–12.
  24. Mungamuri, S.K.; Qiao, R.F.; Yao, S.; Manfredi, J.J.; Gu, W.; Aaronson, S.A. USP7 enforces heterochromatinization of p53 target promoters by protecting SUV39H1 from MDM2-mediated degradation. Cell Rep. 2016, 14, 2528–2537.
  25. Agathanggelou, A.; Smith, E.; Davies, N.J.; Kwok, M.; Zlatanou, A.; Oldreive, C.E.; Mao, J.; Da Costa, D.; Yadollahi, S.; Perry, T. USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. Blood J. Am. Soc. Hematol. 2017, 130, 156–166.
  26. Wang, M.; Zhang, Y.; Wang, T.; Zhang, J.; Zhou, Z.; Sun, Y.; Wang, S.; Shi, Y.; Luan, X.; Zhang, Y. The USP7 inhibitor P5091 induces cell death in ovarian cancers with different P53 status. Cell. Physiol. Biochem. 2017, 43, 1755–1766.
  27. Fan, Y.; Cheng, J.; Vasudevan, S.; Dou, J.; Zhang, H.; Patel, R.; Ma, I.; Rojas, Y.; Zhao, Y.; Yu, Y. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis. 2013, 4, e867.
  28. Peng, Y.; Liu, Y.; Gao, Y.; Yuan, B.; Qi, X.; Fu, Y.; Zhu, Q.; Cao, T.; Zhang, S.; Yin, L. USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis. J. Exp. Clin. Cancer Res. 2019, 38, 1–12.
  29. Ishii, Y.; Kolluri, K.K.; Pennycuick, A.; Nigro, E.; Alrifai, D.; Borg, E.; Falzon, M.; Shah, K.; Kumar, N.; Janes, S.M. BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma. bioRxiv 2020.
  30. Kumar, R.; Taylor, M.; Miao, B.; Ji, Z.; Njauw, J.C.; Jönsson, G.; Frederick, D.T.; Tsao, H. BAP1 has a survival role in cutaneous melanoma. J. Investig. Dermatol. 2015, 135, 1089–1097.
  31. Sime, W.; Niu, Q.; Abassi, Y.; Masoumi, K.C.; Zarrizi, R.; Køhler, J.B.; Kjellström, S.; Lasorsa, V.A.; Capasso, M.; Fu, H. BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma. Cell Death Dis. 2018, 9, 1–16.
  32. Dai, F.; Lee, H.; Zhang, Y.; Zhuang, L.; Yao, H.; Xi, Y.; Xiao, Z.-D.; You, M.J.; Li, W.; Su, X. BAP1 inhibits the ER stress gene regulatory network and modulates metabolic stress response. Proc. Natl. Acad. Sci. USA 2017, 114, 3192–3197.
  33. Zhang, Y.; Shi, J.; Liu, X.; Feng, L.; Gong, Z.; Koppula, P.; Sirohi, K.; Li, X.; Wei, Y.; Lee, H. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat. Cell Biol. 2018, 20, 1181–1192.
  34. Bononi, A.; Giorgi, C.; Patergnani, S.; Larson, D.; Verbruggen, K.; Tanji, M.; Pellegrini, L.; Signorato, V.; Olivetto, F.; Pastorino, S. BAP1 regulates IP3R3-mediated Ca 2+ flux to mitochondria suppressing cell transformation. Nature 2017, 546, 549–553.
  35. Guazzelli, A.; Meysami, P.; Bakker, E.; Demonacos, C.; Giordano, A.; Krstic-Demonacos, M.; Mutti, L. BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment. Int. J. Mol. Sci. 2019, 20, 429.
  36. Sun, C.; Zhao, C.; Li, S.; Wang, J.; Zhou, Q.; Sun, J.; Ding, Q.; Liu, M.; Ding, G. EZH2 Expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis. J. Cancer 2018, 9, 3787.
  37. He, M.; Chaurushiya, M.S.; Webster, J.D.; Kummerfeld, S.; Reja, R.; Chaudhuri, S.; Chen, Y.-J.; Modrusan, Z.; Haley, B.; Dugger, D.L. Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1. Science 2019, 364, 283–285.
  38. Zhang, Y.; Koppula, P.; Gan, B. Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1. Cell Cycle 2019, 18, 773–783.
  39. Guglielmotto, M.; Monteleone, D.; Vasciaveo, V.; Repetto, I.E.; Manassero, G.; Tabaton, M.; Tamagno, E. The decrease of Uch-L1 activity is a common mechanism responsible for Aβ 42 accumulation in Alzheimer’s and vascular disease. Front. Aging Neurosci. 2017, 9, 320.
  40. Bi, H.-L.; Zhang, X.-L.; Zhang, Y.-L.; Xie, X.; Xia, Y.-L.; Du, J.; Li, H.-H. The deubiquitinase UCHL1 regulates cardiac hypertrophy by stabilizing epidermal growth factor receptor. Sci. Adv. 2020, 6, eaax4826.
  41. Gu, Y.; Ding, X.; Huang, J.; Xue, M.; Zhang, J.; Wang, Q.; Yu, H.; Wang, Y.; Zhao, F.; Wang, H. The deubiquitinating enzyme UCHL1 negatively regulates the immunosuppressive capacity and survival of multipotent mesenchymal stromal cells. Cell Death Dis. 2018, 9, 1–13.
  42. Kim, Y.J.; Kim, K.; Lee, Y.Y.; Choo, O.-S.; Jang, J.H.; Choung, Y.-H. Downregulated UCHL1 accelerates gentamicin-induced auditory cell death via autophagy. Mol. Neurobiol. 2019, 56, 7433–7447.
  43. Xu, Y.; Gao, H.; Hu, Y.; Fang, Y.; Qi, C.; Huang, J.; Cai, X.; Wu, H.; Ding, X.; Zhang, Z. High glucose-induced apoptosis and necroptosis in podocytes is regulated by UCHL1 via RIPK1/RIPK3 pathway. Exp. Cell Res. 2019, 382, 111463.
  44. Shen, H.; Sikorska, M.; Leblanc, J.; Walker, P.; Liu, Q. Oxidative stress regulated expression of ubiquitin Carboxyl-terminal Hydrolase-L1: Role in cell survival. Apoptosis 2006, 11, 1049–1059.
  45. Zhang, Y.-P.; Zhu, Y.-B.; Duan, D.D.; Fan, X.-M.; He, Y.; Su, J.-W.; Liu, Y.-L. Serum UCH-L1 as a novel biomarker to predict neuronal apoptosis following deep hypothermic circulatory arrest. Int. J. Med. Sci. 2015, 12, 576.
  46. Li, L.; Tao, Q.; Jin, H.; Van Hasselt, A.; Poon, F.F.; Wang, X.; Zeng, M.-S.; Jia, W.-H.; Zeng, Y.-X.; Chan, A.T. The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin. Cancer Res. 2010, 16, 2949–2958.
  47. Kwon, J.; Wang, Y.-L.; Setsuie, R.; Sekiguchi, S.; Sato, Y.; Sakurai, M.; Noda, M.; Aoki, S.; Yoshikawa, Y.; Wada, K. Two closely related ubiquitin C-terminal hydrolase isozymes function as reciprocal modulators of germ cell apoptosis in cryptorchid testis. Am. J. Pathol. 2004, 165, 1367–1374.
  48. Kwon, J.; Mochida, K.; Wang, Y.-L.; Sekiguchi, S.; Sankai, T.; Aoki, S.; Ogura, A.; Yoshikawa, Y.; Wada, K. Ubiquitin C-terminal hydrolase L-1 is essential for the early apoptotic wave of germinal cells and for sperm quality control during spermatogenesis. Biol. Reprod. 2005, 73, 29–35.
  49. Brinkmann, K.; Zigrino, P.; Witt, A.; Schell, M.; Ackermann, L.; Broxtermann, P.; Schüll, S.; Andree, M.; Coutelle, O.; Yazdanpanah, B. Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep. 2013, 3, 881–891.
  50. Frisan, T.; Coppotelli, G.; Dryselius, R.; Masucci, M.G. Ubiquitin C-terminal hydrolase-L1 interacts with adhesion complexes and promotes cell migration, survival, and anchorage independent growth. FASEB J. 2012, 26, 5060–5070.
  51. Xiang, T.; Li, L.; Yin, X.; Yuan, C.; Tan, C.; Su, X.; Xiong, L.; Putti, T.C.; Oberst, M.; Kelly, K. The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer. PLoS ONE 2012, 7, e29783.
  52. Costes, S.; Gurlo, T.; Rivera, J.F.; Butler, P.C. UCHL1 deficiency exacerbates human islet amyloid polypeptide toxicity in β-cells: Evidence of interplay between the ubiquitin/proteasome system and autophagy. Autophagy 2014, 10, 1004–1014.
  53. Jin, C.; Yu, W.; Lou, X.; Zhou, F.; Han, X.; Zhao, N.; Lin, B. UCHL1 is a putative tumor suppressor in ovarian cancer cells and contributes to cisplatin resistance. J. Cancer 2013, 4, 662.
  54. Wu, H.; Ying, W.; Wang, W.; Li, W.; Feng, X. HIF1α and HIF2α mediated UCHL1 upregulation in hypoxia-induced neuronal injury following neuronal hypoxic ischemic encephalopathy. Int. J. Clin. Exp. Pathol. 2016, 9, 2677–2685.
  55. Wang, S.; Juan, J.; Zhang, Z.; Du, Y.; Xu, Y.; Tong, J.; Cao, B.; Moran, M.F.; Zeng, Y.; Mao, X. Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis. Cell Death Dis. 2017, 8, e3058.
  56. Kaistha, B.P.; Krattenmacher, A.; Fredebohm, J.; Schmidt, H.; Behrens, D.; Widder, M.; Hackert, T.; Strobel, O.; Hoheisel, J.D.; Gress, T.M. The deubiquitinating enzyme USP5 promotes pancreatic cancer via modulating cell cycle regulators. Oncotarget 2017, 8, 66215.
  57. Potu, H.; Kandarpa, M.; Peterson, L.F.; Donato, N.J.; Talpaz, M. Tumor necrosis factor related apoptosis inducing ligand (TRAIL) regulates deubiquitinase USP5 in tumor cells. Oncotarget 2019, 10, 5745.
  58. Fan, X.; Huang, Q.; Ye, X.; Lin, Y.; Chen, Y.; Lin, X.; Qu, J. Drosophila USP5 controls the activation of apoptosis and the Jun N-terminal kinase pathway during eye development. PLoS ONE 2014, 9, e92250.
  59. Liu, Y.; Wang, W.M.; Zou, L.Y.; Li, L.; Feng, L.; Pan, M.Z.; Lv, M.Y.; Cao, Y.; Wang, H.; Kung, H.F. Ubiquitin specific peptidase 5 mediates Histidine-rich protein Hpn induced cell apoptosis in hepatocellular carcinoma through P14-P53 signaling. Proteomics 2017, 17, 1600350.
  60. Liu, Y.; Wang, W.-M.; Lu, Y.-F.; Feng, L.; Li, L.; Pan, M.-Z.; Sun, Y.; Suen, C.-W.; Guo, W.; Pang, J.-X. Usp5 functions as an oncogene for stimulating tumorigenesis in hepatocellular carcinoma. Oncotarget 2017, 8, 50655.
  61. Wu, L.; Zhang, C.; Chu, M.; Fan, Y.; Wei, L.; Li, Z.; Yao, Y.; Zhuang, W. miR-125a suppresses malignancy of multiple myeloma by reducing the deubiquitinase USP5. J. Cell. Biochem. 2020, 121, 642–650.
  62. Vashistha, V.; Bhardwaj, S.; Yadav, B.K.; Yadav, A.K. Depleting deubiquitinating enzymes promotes apoptosis in glioma cell line via RNA binding proteins SF2/ASF1. Biochem. Biophys. Rep. 2020, 24, 100846.
  63. Jing, X.; Chen, Y.; Chen, Y.; Shi, G.; Lv, S.; Cheng, N.; Feng, C.; Xin, Z.; Zhang, L.; Wu, J. Down-regulation of USP8 Inhibits Cholangiocarcinoma Cell Proliferation and Invasion. Cancer Manag. Res. 2020, 12, 2185.
  64. Jeong, M.; Lee, E.; Seong, D.; Seo, J.; Kim, J.; Grootjans, S.; Kim, S.; Vandenabeele, P.; Song, J. USP8 suppresses death receptor-mediated apoptosis by enhancing FLIP L stability. Oncogene 2017, 36, 458–470.
  65. Le Clorennec, C.; Lazrek, Y.; Dubreuil, O.; Sampaio, C.; Larbouret, C.; Lanotte, R.; Poul, M.-A.; Barret, J.-M.; Prost, J.-F.; Pèlegrin, A. ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells. Cell Commun. Signal. 2019, 17, 106.
  66. Yuan, J.; Luo, K.; Zhang, L.; Cheville, J.C.; Lou, Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 2010, 140, 384–396.
  67. Luo, Z.; Zhang, M.; Cui, R.; Tili, E.; Kim, T.; Lee, T.J.; Peng, Y.; Croce, C. A negative feedback regulatory loop between miR-138 and TP53 is mediated by USP10. Oncotarget 2019, 10, 6288.
  68. Niu, J.; Shi, Y.; Xue, J.; Miao, R.; Huang, S.; Wang, T.; Wu, J.; Fu, M.; Wu, Z.H. USP10 inhibits genotoxic NF-κB activation by MCPIP1-facilitated deubiquitination of NEMO. EMBO J. 2013, 32, 3206–3219.
  69. Zhang, M.; Hu, C.; Tong, D.; Xiang, S.; Williams, K.; Bai, W.; Li, G.-M.; Bepler, G.; Zhang, X. Ubiquitin-specific peptidase 10 (USP10) deubiquitinates and stabilizes MutS homolog 2 (MSH2) to regulate cellular sensitivity to DNA damage. J. Biol. Chem. 2016, 291, 10783–10791.
  70. Takahashi, M.; Kitaura, H.; Kakita, A.; Kakihana, T.; Katsuragi, Y.; Nameta, M.; Zhang, L.; Iwakura, Y.; Nawa, H.; Higuchi, M. USP10 is a driver of ubiquitinated protein aggregation and aggresome formation to inhibit apoptosis. IScience 2018, 9, 433–450.
  71. Takahashi, M.; Higuchi, M.; Matsuki, H.; Yoshita, M.; Ohsawa, T.; Oie, M.; Fujii, M. Stress granules inhibit apoptosis by reducing reactive oxygen species production. Mol. Cell. Biol. 2013, 33, 815–829.
  72. Takahashi, M.; Higuchi, M.; Makokha, G.N.; Matsuki, H.; Yoshita, M.; Tanaka, Y.; Fujii, M. HTLV-1 Tax oncoprotein stimulates ROS production and apoptosis in T cells by interacting with USP10. Blood J. Am. Soc. Hematol. 2013, 122, 715–725.
  73. Wang, L.; Wu, D.; Xu, Z. USP10 protects against cerebral ischemia injury by suppressing inflammation and apoptosis through the inhibition of TAK1 signaling. Biochem. Biophys. Res. Commun. 2019, 516, 1272–1278.
  74. Jiangqiao, Z.; Tianyu, W.; Zhongbao, C.; Long, Z.; Jilin, Z.; Xiaoxiong, M.; Tao, Q. Ubiquitin-specific peptidase 10 protects against hepatic ischaemic/reperfusion injury via TAK1 signalling. Front. Immunol. 2020, 11, 506275.
  75. Chen, Q.; Hang, Y.; Zhang, T.; Tan, L.; Li, S.; Jin, Y. USP10 promotes proliferation and migration and inhibits apoptosis of endometrial stromal cells in endometriosis through activating the Raf-1/MEK/ERK pathway. Am. J. Physiol. Cell Physiol. 2018, 315, C863–C872.
  76. Higuchi, M.; Kawamura, H.; Matsuki, H.; Hara, T.; Takahashi, M.; Saito, S.; Saito, K.; Jiang, S.; Naito, M.; Kiyonari, H. USP10 is an essential deubiquitinase for hematopoiesis and inhibits apoptosis of long-term hematopoietic stem cells. Stem Cell Rep. 2016, 7, 1116–1129.
  77. Kim, J.Y.; Lee, D.M.; Woo, H.G.; Kim, K.D.; Lee, H.J.; Kwon, Y.-J.; Choi, K.S. RNAi screening-based identification of USP10 as a novel regulator of paraptosis. Sci. Rep. 2019, 9, 1–12.
  78. Deng, T.; Yan, G.; Song, X.; Xie, L.; Zhou, Y.; Li, J.; Hu, X.; Li, Z.; Hu, J.; Zhang, Y. Deubiquitylation and stabilization of p21 by USP11 is critical for cell-cycle progression and DNA damage responses. Proc. Natl. Acad. Sci. USA 2018, 115, 4678–4683.
  79. Ting, X.; Xia, L.; Yang, J.; He, L.; Si, W.; Shang, Y.; Sun, L. USP11 acts as a histone deubiquitinase functioning in chromatin reorganization during DNA repair. Nucleic Acids Res. 2019, 47, 9721–9740.
  80. Schoenfeld, A.R.; Apgar, S.; Dolios, G.; Wang, R.; Aaronson, S.A. BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage. Mol. Cell. Biol. 2004, 24, 7444–7455.
  81. Zhou, Z.; Luo, A.; Shrivastava, I.; He, M.; Huang, Y.; Bahar, I.; Liu, Z.; Wan, Y. Regulation of XIAP turnover reveals a role for USP11 in promotion of tumorigenesis. EBioMedicine 2017, 15, 48–61.
  82. Lee, E.; Seong, D.; Seo, J.; Jeong, M.; Lee, H.; Song, J. USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics. Cell Death Differ. 2015, 22, 1463–1476.
  83. Xu, Z.; Li, X.; Chen, J.; Zhao, J.; Wang, J.; Ji, Y.; Shen, Y.; Han, L.; Shi, J.; Zhang, D. USP11, deubiquitinating enzyme, associated with neuronal apoptosis following intracerebral hemorrhage. J. Mol. Neurosci. 2016, 58, 16–27.
  84. Li, S.; Hong, X.; Wei, Z.; Xie, M.; Li, W.; Liu, G.; Guo, H.; Yang, J.; Wei, W.; Zhang, S. Ubiquitination of the HPV oncoprotein E6 is critical for E6/E6AP-mediated p53 degradation. Front. Microbiol. 2019, 10, 2483.
  85. Wang, T.S.; Coppens, I.; Saorin, A.; Brady, N.R.; Hamacher-Brady, A. Endolysosomal Targeting of Mitochondria Is Integral to BAX-Mediated Mitochondrial Permeabilization during Apoptosis Signaling. Dev. Cell 2020, 53, 627–645.
  86. Nie, Z.-Y.; Yao, M.; Yang, Z.; Yang, L.; Liu, X.-J.; Yu, J.; Ma, Y.; Zhang, N.; Zhang, X.-Y.; Liu, M.-H. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance. J. Exp. Clin. Cancer Res. 2020, 39, 1–14.
  87. Zou, Q.; Jin, J.; Hu, H.; Li, H.S.; Romano, S.; Xiao, Y.; Nakaya, M.; Zhou, X.; Cheng, X.; Yang, P. USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat. Immunol. 2014, 15, 562–570.
  88. Zhou, L.; Jiang, H.; Du, J.; Li, L.; Li, R.; Lu, J.; Fu, W.; Hou, J. USP15 inhibits multiple myeloma cell apoptosis through activating a feedback loop with the transcription factor NF-κBp65. Exp. Mol. Med. 2018, 50, 1–12.
  89. Chen, X.; Bao, G.; Liu, F. Inhibition of USP15 Prevent Glutamate-Induced Oxidative Damage by Activating Nrf2/HO-1 Signaling Pathway in HT22 Cells. Cell. Mol. Neurobiol. 2020, 40, 999–1020.
  90. Pinto-Fernandez, A.; Salio, M.; Partridge, T.; Chen, J.; Vere, G.; Greenwood, H.; Olie, C.S.; Damianou, A.; Scott, H.C.; Diaz-Saez, L. Deep analysis of the USP18-dependent ISGylome and proteome unveils important roles for USP18 in tumour cell antigenicity and radiosensitivity. bioRxiv 2020.
  91. Santin, I.; Moore, F.; Grieco, F.A.; Marchetti, P.; Brancolini, C.; Eizirik, D.L. USP18 is a key regulator of the interferon-driven gene network modulating pancreatic beta cell inflammation and apoptosis. Cell Death Dis. 2012, 3, e419.
  92. Potu, H.; Sgorbissa, A.; Brancolini, C. Identification of USP18 as an Important Regulator of the Susceptibility to IFN-α and Drug-Induced Apoptosis. Cancer Res. 2010, 70, 655–665.
  93. Manini, I.; Sgorbissa, A.; Potu, H.; Tomasella, A.; Brancolini, C. The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels: Cellular levels of TRAIL influences responsiveness to TRAIL-induced apoptosis. Cancer Biol. Ther. 2013, 14, 1158–1166.
  94. Dagenais-Lussier, X.; Loucif, H.; Cadorel, H.; Blumberger, J.; Isnard, S.; Bego, M.G.; Cohen, É.A.; Routy, J.-P.; van Grevenynghe, J.; Montreal Primary Infection Study Group. USP18 is a significant driver of memory CD4 T-cell reduced viability caused by type I IFN signaling during primary HIV-1 infection. PLoS Pathog. 2019, 15, e1008060.
  95. Diao, W.; Guo, Q.; Zhu, C.; Song, Y.; Feng, H.; Cao, Y.; Du, M.; Chen, H. USP18 promotes cell proliferation and suppressed apoptosis in cervical cancer cells via activating AKT signaling pathway. BMC Cancer 2020, 20, 741.
  96. Duex, J.E.; Comeau, L.; Sorkin, A.; Purow, B.; Kefas, B. Usp18 regulates epidermal growth factor (EGF) receptor expression and cancer cell survival via microRNA-7. J. Biol. Chem. 2011, 286, 25377–25386.
  97. Cai, J.; Liu, T.; Jiang, X.; Guo, C.; Liu, A.; Xiao, X. Downregulation of USP18 inhibits growth and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma cells by suppressing BCL2L1. Exp. Cell Res. 2017, 358, 315–322.
  98. Lai, K.P.; Cheung, A.H.Y.; Tse, W.K.F. Deubiquitinase Usp18 prevents cellular apoptosis from oxidative stress in liver cells. Cell Biol. Int. 2017, 41, 914–921.
  99. Feng, L.; Wang, K.; Tang, P.; Chen, S.; Liu, T.; Lei, J.; Yuan, R.; Hu, Z.; Li, W.; Yu, X. Deubiquitinase USP18 promotes the progression of pancreatic cancer via enhancing the Notch1-c-Myc axis. Aging 2020, 12, 19273.
  100. Ha, J.; Kim, M.; Seo, D.; Park, J.S.; Lee, J.; Lee, J.; Park, S.H. The Deubiquitinating Enzyme USP20 Regulates the TNFα-Induced NF-κB Signaling Pathway through Stabilization of p62. Int. J. Mol. Sci. 2020, 21, 3116.
  101. Kim, J.H.; Seo, D.; Kim, S.J.; Choi, D.W.; Park, J.S.; Ha, J.; Choi, J.; Lee, J.H.; Jung, S.M.; Seo, K.W. The deubiquitinating enzyme USP20 stabilizes ULK1 and promotes autophagy initiation. EMBO Rep. 2018, 19, e44378.
  102. Liu, H.; Liu, N.; Zhao, Y.; Zhu, X.; Wang, C.; Liu, Q.; Gao, C.; Zhao, X.; Li, J. Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling. Aging 2019, 11, 9643.
  103. Lin, Z.; Yang, H.; Kong, Q.; Li, J.; Lee, S.-M.; Gao, B.; Dong, H.; Wei, J.; Song, J.; Zhang, D.D. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol. Cell 2012, 46, 484–494.
  104. Zhou, D.; Liu, P.; Sun, D.; Chen, Z.; Hu, J.; Peng, S.; Liu, Y. USP22 down-regulation facilitates human retinoblastoma cell aging and apoptosis via inhibiting TERT/P53 pathway. Eur. Rev. Med. Pharm. Sci. 2017, 21, 2785–2792.
  105. Ling, S.; Li, J.; Shan, Q.; Dai, H.; Lu, D.; Wen, X.; Song, P.; Xie, H.; Zhou, L.; Liu, J. USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway. Mol. Oncol. 2017, 11, 682–695.
  106. Wang, A.; Ning, Z.; Lu, C.; Gao, W.; Liang, J.; Yan, Q.; Tan, G.; Liu, J. USP22 induces cisplatin resistance in lung adenocarcinoma by regulating γH2AX-mediated DNA damage repair and Ku70/bax-mediated apoptosis. Front. Pharmacol. 2017, 8, 274.
  107. Liang, J.X.; Ning, Z.; Gao, W.; Ling, J.; Wang, A.; Luo, H.F.; Liang, Y.; Yan, Q.; Wang, Z.Y. Ubiquitin-specific protease 22-induced autophagy is correlated with poor prognosis of pancreatic cancer. Oncol. Rep. 2014, 32, 2726–2734.
  108. Li, Z.H.; Yu, Y.; Du, C.; Fu, H.; Wang, J.; Tian, Y. RNA interference-mediated USP22 gene silencing promotes human brain glioma apoptosis and induces cell cycle arrest. Oncol. Lett. 2013, 5, 1290–1294.
  109. Kosinsky, R.L.; Helms, M.; Zerche, M.; Wohn, L.; Dyas, A.; Prokakis, E.; Kazerouni, Z.B.; Bedi, U.; Wegwitz, F.; Johnsen, S.A. USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer. Cell Death Dis. 2019, 10, 1–11.
  110. Roedig, J.; Kowald, L.; Juretschke, T.; Karlowitz, R.; Ahangarian Abhari, B.; Roedig, H.; Fulda, S.; Beli, P.; van Wijk, S.J. USP22 controls necroptosis by regulating receptor-interacting protein kinase 3 ubiquitination. EMBO Rep. 2020, 22, e50163.
  111. Shi, J.-x.; Wang, Q.-j.; Li, H.; Huang, Q. Silencing of USP22 suppresses high glucose-induced apoptosis, ROS production and inflammation in podocytes. Mol. Biosyst. 2016, 12, 1445–1456.
  112. Kovalenko, A.; Chable-Bessia, C.; Cantarella, G.; Israël, A.; Wallach, D.; Courtois, G. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 2003, 424, 801–805.
  113. Brummelkamp, T.R.; Nijman, S.M.; Dirac, A.M.; Bernards, R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 2003, 424, 797–801.
  114. Trompouki, E.; Hatzivassiliou, E.; Tsichritzis, T.; Farmer, H.; Ashworth, A.; Mosialos, G. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 2003, 424, 793–796.
  115. Schlicher, L.; Wissler, M.; Preiss, F.; Brauns-Schubert, P.; Jakob, C.; Dumit, V.; Borner, C.; Dengjel, J.; Maurer, U. SPATA 2 promotes CYLD activity and regulates TNF-induced NF-κB signaling and cell death. EMBO Rep. 2016, 17, 1485–1497.
  116. Ang, R.L.; Sundberg, J.P.; Sun, S.-C.; Gillespie, V.L.; Heeger, P.; Xiong, H.; Lira, S.A.; Ting, A.T. Immune dysregulation in SHARPIN-deficient mice is dependent on CYLD-mediated cell death. bioRxiv 2020.
  117. Moquin, D.M.; McQuade, T.; Chan, F.K.-M. CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis. PLoS ONE 2013, 8, e76841.
  118. Legarda, D.; Justus, S.J.; Ang, R.L.; Rikhi, N.; Li, W.; Moran, T.M.; Zhang, J.; Mizoguchi, E.; Zelic, M.; Kelliher, M.A. CYLD proteolysis protects macrophages from TNF-mediated auto-necroptosis induced by LPS and licensed by type I IFN. Cell Rep. 2016, 15, 2449–2461.
  119. Huang, C.; Liu, J.; Pan, X.; Peng, C.; Xiong, B.; Feng, M.; Yang, X. miR-454 promotes survival and induces oxaliplatin resistance in gastric carcinoma cells by targeting CYLD. Exp. Ther. Med. 2020, 19, 3604–3610.
  120. Lin, Y.; Wang, L.; Luo, W.; Zhou, X.; Chen, Y.; Yang, K.; Liao, J.; Wu, D.; Cai, L. CYLD Promotes Apoptosis of Nasopharyngeal Carcinoma Cells by Regulating NDRG1. Cancer Manag. Res. 2020, 12, 10639.
  121. Qi, L.; Zang, H.; Wu, W.; Nagarkatti, P.; Nagarkatti, M.; Liu, Q.; Robbins, J.; Wang, X.; Cui, T. CYLD exaggerates pressure overload-induced cardiomyopathy via suppressing autolysosome efflux in cardiomyocytes. J. Mol. Cell. Cardiol. 2020, 145, 59–73.
  122. Priem, D.; Devos, M.; Druwé, S.; Martens, A.; Slowicka, K.; Ting, A.T.; Pasparakis, M.; Declerq, W.; Vandenabeele, P.; van Loo, G. A20 protects cells from TNF-induced apoptosis through linear ubiquitin-dependent and-independent mechanisms. Cell Death Dis. 2019, 10, 1–16.
  123. Feoktistova, M.; Makarov, R.; Brenji, S.; Schneider, A.T.; Hooiveld, G.J.; Luedde, T.; Leverkus, M.; Yazdi, A.S.; Panayotova-Dimitrova, D. A20 Promotes Ripoptosome Formation and TNF-Induced Apoptosis via cIAPs Regulation and NIK Stabilization in Keratinocytes. Cells 2020, 9, 351.
  124. Li, Y.; Mooney, E.C.; Xia, X.-J.; Gupta, N.; Sahingur, S.E. A20 Restricts Inflammatory Response and Desensitizes Gingival Keratinocytes to Apoptosis. Front. Immunol. 2020, 11, 365.
  125. Chen, X.; Qian, B.; Kong, X.; Hao, J.; Ye, Y.; Yang, K.; Xu, T.; Zhang, F. A20 protects neuronal apoptosis stimulated by lipopolysaccharide-induced microglial exosomes. Neurosci. Lett. 2019, 712, 134480.
  126. Bellail, A.C.; Olson, J.J.; Yang, X.; Chen, Z.J.; Hao, C. A20 ubiquitin ligase–mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov. 2012, 2, 140–155.
  127. Jin, Z.; Li, Y.; Pitti, R.; Lawrence, D.; Pham, V.C.; Lill, J.R.; Ashkenazi, A. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009, 137, 721–735.
  128. Duong, B.H.; Onizawa, M.; Oses-Prieto, J.A.; Advincula, R.; Burlingame, A.; Malynn, B.A.; Ma, A. A20 restricts ubiquitination of pro-interleukin-1β protein complexes and suppresses NLRP3 inflammasome activity. Immunity 2015, 42, 55–67.
  129. Ding, X.; Jing, N.; Shen, A.; Guo, F.; Song, Y.; Pan, M.; Ma, X.; Zhao, L.; Zhang, H.; Wu, L. MiR-21-5p in macrophage-derived extracellular vesicles affects podocyte pyroptosis in diabetic nephropathy by regulating A20. J. Endocrinol. Investig. 2020.
  130. Slowicka, K.; Serramito-Gómez, I.; Boada-Romero, E.; Martens, A.; Sze, M.; Petta, I.; Vikkula, H.K.; De Rycke, R.; Parthoens, E.; Lippens, S. Physical and functional interaction between A20 and ATG16L1-WD40 domain in the control of intestinal homeostasis. Nat. Commun. 2019, 10, 1–15.
  131. Keusekotten, K.; Elliott, P.R.; Glockner, L.; Fiil, B.K.; Damgaard, R.B.; Kulathu, Y.; Wauer, T.; Hospenthal, M.K.; Gyrd-Hansen, M.; Krappmann, D. OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. Cell 2013, 153, 1312–1326.
  132. Fiil, B.K.; Damgaard, R.B.; Wagner, S.A.; Keusekotten, K.; Fritsch, M.; Bekker-Jensen, S.; Mailand, N.; Choudhary, C.; Komander, D.; Gyrd-Hansen, M. OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol. Cell 2013, 50, 818–830.
  133. Fiil, B.K.; Gyrd-Hansen, M. OTULIN deficiency causes auto-inflammatory syndrome. Cell Res. 2016, 26, 1176–1177.
  134. Damgaard, R.B.; Elliott, P.R.; Swatek, K.N.; Maher, E.R.; Stepensky, P.; Elpeleg, O.; Komander, D.; Berkun, Y. OTULIN deficiency in ORAS causes cell type-specific LUBAC degradation, dysregulated TNF signalling and cell death. EMBO Mol. Med. 2019, 11, e9324.
  135. Heger, K.; Wickliffe, K.E.; Ndoja, A.; Zhang, J.; Murthy, A.; Dugger, D.L.; Maltzman, A.; e Melo, F.D.S.; Hung, J.; Zeng, Y. OTULIN limits cell death and inflammation by deubiquitinating LUBAC. Nature 2018, 559, 120–124.
  136. Douglas, T.; Saleh, M. Post-translational modification of OTULIN regulates ubiquitin dynamics and cell death. Cell Rep. 2019, 29, 3652–3663.e5.
  137. Damgaard, R.B.; Jolin, H.E.; Allison, M.E.; Davies, S.E.; Titheradge, H.L.; McKenzie, A.N.; Komander, D. OTULIN protects the liver against cell death, inflammation, fibrosis, and cancer. Cell Death Differ. 2020, 27, 1457–1474.
  138. Verboom, L.; Martens, A.; Priem, D.; Hoste, E.; Sze, M.; Vikkula, H.; Van Hove, L.; Voet, S.; Roels, J.; Maelfait, J. OTULIN prevents liver inflammation and hepatocellular carcinoma by inhibiting FADD-and RIPK1 kinase-mediated hepatocyte apoptosis. Cell Rep. 2020, 30, 2237–2247.e6.
  139. Sun, X.X.; Challagundla, K.B.; Dai, M.S. Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1. EMBO J. 2012, 31, 576–592.
  140. Chen, Y.; Wang, Y.-G.; Li, Y.; Sun, X.-X.; Dai, M.-S. Otub1 stabilizes MDMX and promotes its proapoptotic function at the mitochondria. Oncotarget 2017, 8, 11053.
  141. Karunarathna, U.; Kongsema, M.; Zona, S.; Gong, C.; Cabrera, E.; Gomes, A.R.; Man, E.P.; Khongkow, P.; Tsang, J.W.; Khoo, U.-S. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance. Oncogene 2016, 35, 1433–1444.
  142. Ni, Q.; Chen, J.; Li, X.; Xu, X.; Zhang, N.; Zhou, A.; Zhou, B.; Lu, Q.; Chen, Z. Expression of OTUB1 in hepatocellular carcinoma and its effects on HCC cell migration and invasion. Acta Biochim. Biophys. Sin. 2017, 49, 680–688.
  143. Xie, L.; Li, A.; Shen, J.; Cao, M.; Ning, X.; Yuan, D.; Ji, Y.; Wang, H.; Ke, K. OTUB1 attenuates neuronal apoptosis after intracerebral hemorrhage. Mol. Cell. Biochem. 2016, 422, 171–180.
  144. Goncharov, T.; Niessen, K.; De Almagro, M.C.; Izrael-Tomasevic, A.; Fedorova, A.V.; Varfolomeev, E.; Arnott, D.; Deshayes, K.; Kirkpatrick, D.S.; Vucic, D. OTUB1 modulates c-IAP1 stability to regulate signalling pathways. EMBO J. 2013, 32, 1103–1114.
  145. Liu, T.; Jiang, L.; Tavana, O.; Gu, W. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11. Cancer Res. 2019, 79, 1913–1924.
  146. Tian, Z.; D’Arcy, P.; Wang, X.; Ray, A.; Tai, Y.-T.; Hu, Y.; Carrasco, R.D.; Richardson, P.; Linder, S.; Chauhan, D. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood J. Am. Soc. Hematol. 2014, 123, 706–716.
  147. Wang, X.; Mazurkiewicz, M.; Hillert, E.-K.; Olofsson, M.H.; Pierrou, S.; Hillertz, P.; Gullbo, J.; Selvaraju, K.; Paulus, A.; Akhtar, S. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Sci. Rep. 2016, 6, 1–15.
  148. Paulus, A.; Akhtar, S.; Caulfield, T.; Samuel, K.; Yousaf, H.; Bashir, Y.; Paulus, S.; Tran, D.; Hudec, R.; Cogen, D. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib-or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. Blood Cancer J. 2016, 6, e492.
  149. Chitta, K.; Paulus, A.; Akhtar, S.; Blake, M.K.K.; Caulfield, T.R.; Novak, A.J.; Ansell, S.M.; Advani, P.; Ailawadhi, S.; Sher, T. Targeted inhibition of the deubiquitinating enzymes, USP 14 and UCHL 5, induces proteotoxic stress and apoptosis in W aldenström macroglobulinaemia tumour cells. Br. J. Haematol. 2015, 169, 377–390.
  150. Jiang, L.; Sun, Y.; Wang, J.; He, Q.; Chen, X.; Lan, X.; Chen, J.; Dou, Q.P.; Shi, X.; Liu, J. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma. J. Exp. Clin. Cancer Res. 2019, 38, 1–14.
  151. Sha, B.; Chen, X.; Wu, H.; Li, M.; Shi, J.; Wang, L.; Liu, X.; Chen, P.; Hu, T.; Li, P. Deubiquitylatinase inhibitor b-AP15 induces c-Myc-Noxa-mediated apoptosis in esophageal squamous cell carcinoma. Apoptosis 2019, 24, 826–836.
  152. Chen, J.; Chen, X.; Xu, D.; Yang, L.; Yang, Z.; Yang, Q.; Yan, D.; Zhang, P.; Feng, D.; Liu, J. Autophagy Induced by Proteasomal DUB inhibitor NiPT Restricts NiPT-mediated cancer cell death. Front. Oncol. 2020, 10, 348.
  153. Fukui, S.; Nagasaka, K.; Miyagawa, Y.; Kikuchi-Koike, R.; Kawata, Y.; Kanda, R.; Ichinose, T.; Sugihara, T.; Hiraike, H.; Wada-Hiraike, O. The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-β/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget 2019, 10, 5932.
  154. Da Liu, Z.S.; Wang, X.; Ouyang, L. Ubiquitin C-Terminal Hydrolase L5 (UCHL5) Accelerates the Growth of Endometrial Cancer via Activating the Wnt/β-Catenin Signaling Pathway. Front. Oncol. 2020, 10, 865.
  155. Qu, Z.; Zhou, J.; Zhou, Y.; Xie, Y.; Jiang, Y.; Wu, J.; Luo, Z.; Liu, G.; Yin, L.; Zhang, X.-L. Mycobacterial EST12 activates a RACK1–NLRP3–gasdermin D pyroptosis–IL-1β immune pathway. Sci. Adv. 2020, 6, eaba4733.
  156. Ma, Y.-S.; Wang, X.-F.; Zhang, Y.-J.; Luo, P.; Long, H.-D.; Li, L.; Yang, H.-Q.; Xie, R.-T.; Jia, C.-Y.; Lu, G.-X. Inhibition of USP14 Deubiquitinating Activity as a Potential Therapy for Tumors with p53 Deficiency. Mol. Ther. Oncolytics 2020, 16, 147–157.
  157. Xu, L.; Wang, J.; Yuan, X.; Yang, S.; Xu, X.; Li, K.; He, Y.; Wei, L.; Zhang, J.; Tian, Y. IU1 suppresses proliferation of cervical cancer cells through MDM2 degradation. Int. J. Biol. Sci. 2020, 16, 2951.
  158. Xia, X.; Huang, C.; Liao, Y.; Liu, Y.; He, J.; Guo, Z.; Jiang, L.; Wang, X.; Liu, J.; Huang, H. Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide. J. Exp. Clin. Cancer Res. 2019, 38, 1–17.
  159. Liao, Y.; Xia, X.; Liu, N.; Cai, J.; Guo, Z.; Li, Y.; Jiang, L.; Dou, Q.P.; Tang, D.; Huang, H. Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination. Oncogene 2018, 37, 1896–1910.
  160. Didier, R.; Mallavialle, A.; Jouira, R.B.; Domdom, M.A.; Tichet, M.; Auberger, P.; Luciano, F.; Ohanna, M.; Tartare-Deckert, S.; Deckert, M. Targeting the proteasome-associated deubiquitinating enzyme USP14 impairs melanoma cell survival and overcomes resistance to MAPK-targeting therapies. Mol. Cancer Ther. 2018, 17, 1416–1429.
  161. Fu, Y.; Ma, G.; Liu, G.; Li, B.; Li, H.; Hao, X.; Liu, L. USP 14 as a novel prognostic marker promotes cisplatin resistance via Akt/ERK signaling pathways in gastric cancer. Cancer Med. 2018, 7, 5577–5588.
  162. Wu, N.; Zhang, C.; Bai, C.; Han, Y.P.; Li, Q. MiR-4782-3p inhibited non-small cell lung cancer growth via USP14. Cell. Physiol. Biochem. 2014, 33, 457–467.
  163. Xu, J.; Deng, Y.; Wang, Y.; Sun, X.; Chen, S.; Fu, G. SPAG5-AS1 inhibited autophagy and aggravated apoptosis of podocytes via SPAG5/AKT/mTOR pathway. Cell Prolif. 2020, 53, e12738.
  164. Han, K.H.; Kwak, M.; Lee, T.H.; Park, M.-S.; Jeong, I.-H.; Kim, M.J.; Jin, J.-O.; Lee, P.C.-W. USP14 inhibition regulates tumorigenesis by inducing autophagy in lung cancer in vitro. Int. J. Mol. Sci. 2019, 20, 5300.
  165. Moghadami, A.A.; Aboutalebi Vand Beilankouhi, E.; Kalantary-Charvadeh, A.; Hamzavi, M.; Mosayyebi, B.; Sedghi, H.; Ghorbani Haghjo, A.; Nazari Soltan Ahmad, S. Inhibition of USP14 induces ER stress-mediated autophagy without apoptosis in lung cancer cell line A549. Cell Stress Chaperones 2020, 25, 909–917.
  166. Song, C.; Ma, R.; Yang, X.; Pang, S. The deubiquitinating enzyme USP14 regulates leukemic chemotherapy drugs-induced cell apoptosis by suppressing ubiquitination of Aurora kinase B. Cell. Physiol. Biochem. 2017, 42, 965–973.
  167. Vogel, R.I.; Pulver, T.; Heilmann, W.; Mooneyham, A.; Mullany, S.; Zhao, X.; Shahi, M.; Richter, J.; Klein, M.; Chen, L. USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment. Oncotarget 2016, 7, 30962.
  168. Dong, Y.; Hakimi, M.-A.; Chen, X.; Kumaraswamy, E.; Cooch, N.S.; Godwin, A.K.; Shiekhattar, R. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol. Cell 2003, 12, 1087–1099.
  169. Chen, X.; Arciero, C.A.; Wang, C.; Broccoli, D.; Godwin, A.K. BRCC36 is essential for ionizing radiation–induced BRCA1 phosphorylation and nuclear foci formation. Cancer Res. 2006, 66, 5039–5046.
  170. Py, B.F.; Kim, M.-S.; Vakifahmetoglu-Norberg, H.; Yuan, J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol. Cell 2013, 49, 331–338.
  171. Singh, M.; Kumari, B.; Yadav, U.C. Regulation of oxidized LDL-induced inflammatory process through NLRP3 inflammasome activation by the deubiquitinating enzyme BRCC36. Inflamm. Res. 2019, 68, 999–1010.
  172. Zhou, L.; Liu, T.; Huang, B.; Luo, M.; Chen, Z.; Zhao, Z.; Wang, J.; Leung, D.; Yang, X.; Chan, K.W. Excessive deubiquitination of NLRP3-R779C variant contributes to very-early-onset inflammatory bowel disease development. J. Allergy Clin. Immunol. 2020, 147, 267–279.
  173. Rao, Z.; Chen, X.; Wu, J.X.; Xiao, M.; Zhang, J.; Zhang, H.; Yang, S.; Wang, X.; Fang, L.; Wang, B. Vitamin D receptor inhibits NLRP3 activation by impeding its deubiquitination mediated by BRCC3. Front. Immunol. 2019, 10, 2783.
  174. Chen, X.; Shi, H.; Bi, X.; Li, Y.; Huang, Z. Targeting the deubiquitinase STAMBPL1 triggers apoptosis in prostate cancer cells by promoting XIAP degradation. Cancer Lett. 2019, 456, 49–58.
  175. Shahriyar, S.A.; Woo, S.M.; Seo, S.U.; Min, K.-J.; Kwon, T.K. Cepharanthine enhances TRAIL-mediated apoptosis through STAMBPL1-mediated downregulation of survivin expression in renal carcinoma cells. Int. J. Mol. Sci. 2018, 19, 3280.
  176. Yu, D.J.; Qian, J.; Jin, X.; Li, J.; Guo, C.X.; Yue, X.C. STAMBPL1 knockdown has antitumour effects on gastric cancer biological activities. Oncol. Lett. 2019, 18, 4421–4428.
  177. Ning, F.; Xin, H.; Liu, J.; Lv, C.; Xin, X.; Wang, M.; Wang, Y.; Zhang, W.; Zhang, X. Structure and function of USP5: Insight into physiological and pathophysiological roles. Pharmacol. Res. 2019, 157, 104557.
  178. Bhattacharya, S.; Chakraborty, D.; Basu, M.; Ghosh, M.K. Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases. Signal Transduct. Target. Ther. 2018, 3, 1–12.
  179. Li, M.; Brooks, C.L.; Kon, N.; Gu, W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 2004, 13, 879–886.
  180. Kon, N.; Kobayashi, Y.; Li, M.; Brooks, C.; Ludwig, T.; Gu, W. Inactivation of HAUSP in vivo modulates p53 function. Oncogene 2010, 29, 1270–1279.
  181. Dufner, A.; Knobeloch, K.-P. Ubiquitin-specific protease 8 (USP8/UBPy): A prototypic multidomain deubiquitinating enzyme with pleiotropic functions. Biochem. Soc. Trans. 2019, 47, 1867–1879.
  182. Bhattacharya, U.; Neizer-Ashun, F.; Mukherjee, P.; Bhattacharya, R. When the chains do not break: The role of USP10 in physiology and pathology. Cell Death Dis. 2020, 11, 1–10.
  183. Chou, C.-K.; Chang, Y.-T.; Korinek, M.; Chen, Y.-T.; Yang, Y.-T.; Leu, S.; Lin, I.; Tang, C.-J.; Chiu, C.-C. The regulations of deubiquitinase USP15 and its pathophysiological mechanisms in diseases. Int. J. Mol. Sci. 2017, 18, 483.
  184. Kang, J.A.; Jeon, Y.J. Emerging roles of USP18: From biology to pathophysiology. Int. J. Mol. Sci. 2020, 21, 6825.
  185. Wu, C.; Luo, K.; Zhao, F.; Yin, P.; Song, Y.; Deng, M.; Huang, J.; Chen, Y.; Li, L.; Lee, S. USP20 positively regulates tumorigenesis and chemoresistance through β-catenin stabilization. Cell Death Differ. 2018, 25, 1855–1869.
  186. Shanmugam, I.; Abbas, M.; Ayoub, F.; Mirabal, S.; Bsaili, M.; Caulder, E.K.; Weinstock, D.M.; Tomkinson, A.E.; Hromas, R.; Shaheen, M. Ubiquitin-specific peptidase 20 regulates Rad17 stability, checkpoint kinase 1 phosphorylation and DNA repair by homologous recombination. J. Biol. Chem. 2014, 289, 22739–22748.
  187. Lu, X.-Y.; Shi, X.-J.; Hu, A.; Wang, J.-Q.; Ding, Y.; Jiang, W.; Sun, M.; Zhao, X.; Luo, J.; Qi, W. Feeding induces cholesterol biosynthesis via the mTORC1–USP20–HMGCR axis. Nature 2020, 588, 479–484.
  188. Melo-Cardenas, J.; Zhang, Y.; Zhang, D.D.; Fang, D. Ubiquitin-specific peptidase 22 functions and its involvement in disease. Oncotarget 2016, 7, 44848.
  189. Suenaga, N.; Kuramitsu, M.; Komure, K.; Kanemaru, A.; Takano, K.; Ozeki, K.; Nishimura, Y.; Yoshida, R.; Nakayama, H.; Shinriki, S. Loss of tumor suppressor CYLD expression triggers cisplatin resistance in oral squamous cell carcinoma. Int. J. Mol. Sci. 2019, 20, 5194.
  190. Yang, C.; Ran, Q.; Zhou, Y.; Liu, S.; Zhao, C.; Yu, X.; Zhu, F.; Ji, Y.; Du, Q.; Yang, T. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis. Apoptosis 2020, 25, 441–455.
  191. Massoumi, R.; Chmielarska, K.; Hennecke, K.; Pfeifer, A.; Fässler, R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-κB signaling. Cell 2006, 125, 665–677.
  192. Lork, M.; Verhelst, K.; Beyaert, R. CYLD, A20 and OTULIN deubiquitinases in NF-κ B signaling and cell death: So similar, yet so different. Cell Death Differ. 2017, 24, 1172–1183.
  193. Komander, D.; Reyes-Turcu, F.; Licchesi, J.D.; Odenwaelder, P.; Wilkinson, K.D.; Barford, D. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 2009, 10, 466–473.
  194. Wang, L.; Du, F.; Wang, X. TNF-α induces two distinct caspase-8 activation pathways. Cell 2008, 133, 693–703.
  195. Draber, P.; Kupka, S.; Reichert, M.; Draberova, H.; Lafont, E.; de Miguel, D.; Spilgies, L.; Surinova, S.; Taraborrelli, L.; Hartwig, T. LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes. Cell Rep. 2015, 13, 2258–2272.
  196. Reiley, W.; Zhang, M.; Wu, X.; Granger, E.; Sun, S.-C. Regulation of the deubiquitinating enzyme CYLD by IκB kinase gamma-dependent phosphorylation. Mol. Cell. Biol. 2005, 25, 3886–3895.
  197. Hutti, J.E.; Shen, R.R.; Abbott, D.W.; Zhou, A.Y.; Sprott, K.M.; Asara, J.M.; Hahn, W.C.; Cantley, L.C. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKε promotes cell transformation. Mol. Cell 2009, 34, 461–472.
  198. Xu, X.; Kalac, M.; Markson, M.; Chan, M.; Brody, J.D.; Bhagat, G.; Ang, R.L.; Legarda, D.; Justus, S.J.; Liu, F. Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL). Cell Death Dis. 2020, 11, 1–14.
  199. Hitomi, J.; Christofferson, D.E.; Ng, A.; Yao, J.; Degterev, A.; Xavier, R.J.; Yuan, J. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008, 135, 1311–1323.
  200. Wu, Y.; He, X.; Huang, N.; Yu, J.; Shao, B. A20: A master regulator of arthritis. Arthritis Res. Ther. 2020, 22, 1–15.
  201. Wertz, I.E.; O’Rourke, K.M.; Zhou, H.; Eby, M.; Aravind, L.; Seshagiri, S.; Wu, P.; Wiesmann, C.; Baker, R.; Boone, D.L. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 2004, 430, 694–699.
  202. Weinelt, N.; van Wijk, S.J. Ubiquitin-dependent and-independent functions of OTULIN in cell fate control and beyond. Cell Death Differ. 2020, 28, 493–504.
  203. Damgaard, R.B.; Walker, J.A.; Marco-Casanova, P.; Morgan, N.V.; Titheradge, H.L.; Elliott, P.R.; McHale, D.; Maher, E.R.; McKenzie, A.N.; Komander, D. The deubiquitinase OTULIN is an essential negative regulator of inflammation and autoimmunity. Cell 2016, 166, 1215–1230.e20.
  204. Saldana, M.; VanderVorst, K.; Berg, A.L.; Lee, H.; Carraway, K.L. Otubain 1: A non-canonical deubiquitinase with an emerging role in cancer. Endocr. Relat. Cancer 2019, 26, R1–R14.
  205. Carbone, M.; Harbour, J.W.; Brugarolas, J.; Bononi, A.; Pagano, I.; Dey, A.; Krausz, T.; Pass, H.I.; Yang, H.; Gaudino, G. Biological mechanisms and clinical significance of BAP1 mutations in human cancer. Cancer Discov. 2020, 10, 1103–1120.
  206. Luo, H.; Jing, B.; Xia, Y.; Zhang, Y.; Hu, M.; Cai, H.; Tong, Y.; Zhou, L.; Yang, L.; Yang, J. WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia. Cancer Cell Int. 2019, 19, 1–14.
  207. Patel, K.; Ahmed, Z.S.; Huang, X.; Yang, Q.; Ekinci, E.; Neslund-Dudas, C.M.; Mitra, B.; Elnady, F.A.; Ahn, Y.-H.; Yang, H. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: Lessons from rational design, nature and old drug reposition. Future Med. Chem. 2018, 10, 2087–2108.
  208. Woo, S.M.; Seo, S.U.; Kubatka, P.; Min, K.-J.; Kwon, T.K. Honokiol Enhances TRAIL-Mediated Apoptosis through STAMBPL1-Induced Survivin and c-FLIP Degradation. Biomolecules 2019, 9, 838.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Video Production Service
Feedback